Letters to the Editor

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, USA;
Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, USA;
Divisions of Hematology and Oncology, Washington University School of Medicine in St. Louis, USA
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA;
Haematologica Early view Jun 4, 2020 https://doi.org/10.3324/haematol.2020.252569